Guggenheim raised the firm’s price target on Nanobiotix (NBTX) to $36 from $26 and keeps a Buy rating on the shares. The firm is updating its model to reflect second half results, as well as updating estimates and assumptions to reflect increased conviction in the JNJ-1900 opportunity, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBTX:
- Nanobiotix: Late-Stage NBTXR3 Pipeline and Partnerships Underpin Buy-Rated Risk-Reward Profile
- Nanobiotix price target raised to $37 from $26 at Leerink
- Nanobiotix Extends Cash Runway to 2028 as JNJ-1900 Oncology Program Advances and 2025 Results Filed
- Robust Phase 2 CONVERGE Data for JNJ-1900 Underpin Buy Rating and €32 Price Target on Nanobiotix
- Nanobiotix price target raised to EUR 32 from EUR 23 at H.C. Wainwright